ReviewMicroorganisms2021
Promising Drug Targets and Compounds with Anti-
Review in Microorganisms, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 45 citations in OpenAlex.
- Photodynamic Therapy for Toxoplasma gondii Infections Using Rose Bengal.Luminescence : the journal of biological and chemical luminescence · 2026Article
- Intravitreal cotrimoxazole as adjuvant therapy for active ocular toxoplasmosis: a case series and literature review.Journal of ophthalmic inflammation and infection · 2026Article
- Therapeutic Antitoxoplasmosis Potential ofJournal of tropical medicine · 2026Article
- A Structural In Silico Analysis of Novel Epitopes fromInternational journal of molecular sciences · 2025Article
- Novel drug candidates targetingFrontiers in pharmacology · 2025Article
- Comparative evaluation of silver nanoparticles and human platelet rich-plasma versus traditional therapy in the treatment of murine chronic toxoplasmosis.Journal of parasitic diseases : official organ of the Indian Society for Parasitology · 2024Article
- Construction of luciferase-expressing Neospora caninum and drug screening.Parasites & vectors · 2024Article
- Formulation and evaluation of atovaquone-loaded macrophage-derived exosomes againstMicrobiology spectrum · 2024Article
- Mitochondrial dysfunction induced by bedaquiline as an anti-Toxoplasma alternative.Veterinary research · 2023Article
- Anti-Parasitology · 2023Article
- CD4Vaccines · 2023Article
- Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine againstVaccines · 2023Review
- Two small-molecule inhibitors ofFrontiers in cellular and infection microbiology · 2023Article
- A novelFrontiers in microbiology · 2023Article
- Evaluation of the Combined Effect of Artemisinin and Ferroptosis Inducer RSL3 againstInternational journal of molecular sciences · 2022Article
- New Nucleic Base-Tethered Trithiolato-Bridged Dinuclear Ruthenium(II)-Arene Compounds: Synthesis and Antiparasitic Activity.Molecules (Basel, Switzerland) · 2022Article
- In Vitro and In Vivo Activities of Tilmicosin and Acetylisovaleryltylosin Tartrate againstInternational journal of molecular sciences · 2022Article
- Drug Repurposing Based on Protozoan Proteome: In Vitro Evaluation of In Silico Screened Compounds againstPharmaceutics · 2022Article
- The anti-Frontiers in veterinary science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Toxoplasmosis is a parasitic disease caused by the globally distributed protozoan parasite
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.